Streptococcus pneumoniae serotype 1

Streptococcus pneumoniae serotype 1 is a specific capsular variant (“serotype”) of the bacterium Streptococcus pneumoniae. This Gram-positive, lancet-shaped diplococcus is one of over 100 known pneumococcal serotypes distinguished by their unique polysaccharide capsules. Serotype 1 is globally recognized as one of the most prevalent causes of invasive pneumococcal diseases—such as bacteremia, meningitis, and severe community-acquired pneumonia—and has been responsible for major outbreaks worldwide[3][4]. It exhibits high virulence but typically shows low genetic diversity and short duration in nasopharyngeal colonization compared to other types[7]. Molecular studies have identified dominant sequence types within this serotype—such as ST217 in Africa/Asia and ST306 in Europe/Oceania—with distinct regional distributions and outbreak associations[3][7]. Serotype 1 strains possess numerous virulence factors common to S. pneumoniae—including capsular polysaccharide for immune evasion; surface adhesins like pilus proteins; exoenzymes that degrade host barriers; metal ion uptake systems; proteases that impair neutrophil function; and toxins such as pneumolysin that damage epithelial cells and promote inflammation[2]. While generally susceptible to first-line antibiotics like penicillin, macrolides, and quinolones, resistance genes can be present depending on local epidemiology[1]. Vaccination with conjugate vaccines targeting this capsule type has significantly reduced its incidence where implemented. However, due to its role as an entire bacterial strain rather than a discrete molecular target such as an enzyme or receptor protein relevant for drug discovery campaigns or targeted therapies, “Streptococcus pneumoniae serotype 1” should not be classified as a therapeutic target molecule/receptor. Note: The entry "Streptococcus pneumoniae serotype 1" refers to an entire bacterial strain defined by its capsule type—not a single molecular entity suitable for direct pharmacological targeting—so it does not fit standard definitions used for drug targets like receptors or enzymes. This makes it *incorrect* if used where only individual molecules/proteins are expected.[3][4]

Other names

S. pneumoniae serotype 1Pneumococcus serotype 1Streptococcus pneumoniae type 1

Inhibition of bacterial cell wall synthesis (beta-lactams); Inhibition of protein synthesis (macrolides)